BioXcel Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016
Revenue	1.38	0.38	0	0	0	0	0	0
Revenue Growth (YoY)	268.00%	-	-	-	-	-	-	-
Cost of Revenue	1.26	0.02	0	0	0	0	0	0
Gross Profit	0.12	0.36	0	0	0	0	0	0
Selling, General & Admin	83.41	68.76	54.23	24.3	7.8	5.4	1.85	0.72
Research & Development	84.33	91.24	52.71	58	25.8	14.56	2.69	1.4
Other Operating Expenses	4.16	0	0	0	0	0	0	0
Operating Expenses	171.9	160	106.94	82.3	33.6	19.96	4.54	2.12
Operating Income	-171.78	-159.65	-106.94	-82.3	-33.6	-19.96	-4.54	-2.12
Interest Expense / Income	13.31	8.21	0.04	0.03	0.02	0	0	0
Other Expense / Income	-6.04	-2.1	-0.04	-0.16	-0.65	-0.69	0	-
Pretax Income	-179.05	-165.76	-106.93	-82.17	-32.97	-19.27	-4.54	-2.12
Net Income	-179.05	-165.76	-106.93	-82.17	-32.97	-19.27	-4.54	-2.12
Shares Outstanding (Basic)	29	28	26	22	16	15	10	9
Shares Outstanding (Diluted)	29	28	26	22	16	15	10	9
Shares Change	3.98%	6.23%	21.63%	33.11%	11.79%	50.45%	2.16%	-
EPS (Basic)	-6.15	-5.92	-4.05	-3.79	-2.02	-1.32	-0.47	-0.22
EPS (Diluted)	-6.15	-5.92	-4.05	-3.79	-2.02	-1.32	-0.47	-0.22
Free Cash Flow	-155.03	-135.48	-82.6	-66.67	-27.97	-13.85	-2.2	-1.3
Free Cash Flow Per Share	-5.32	-4.84	-3.13	-3.08	-1.72	-0.95	-0.23	-0.14
Gross Margin	8.70%	94.67%	-	-	-	-	-	-
Operating Margin	-12447.97%	-42572.00%	-	-	-	-	-	-
Profit Margin	-12974.86%	-44201.87%	-	-	-	-	-	-
Free Cash Flow Margin	-11233.77%	-36128.00%	-	-	-	-	-	-
EBITDA	-165.42	-157.22	-106.59	-81.95	-32.79	-19.25	-4.54	-2.12
EBITDA Margin	-11987.03%	-41924.53%	-	-	-	-	-	-
Depreciation & Amortization	0.32	0.33	0.3	0.19	0.16	0.02	0	0
EBIT	-165.74	-157.54	-106.89	-82.14	-32.95	-19.27	-4.54	-2.12
EBIT Margin	-12010.07%	-42011.73%	-	-	-	-	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).